Anti-PDGF, anti-VEGF combination for neovascular AMD well tolerated

MIAMI — An anti-PDGF agent combined with an anti-VEGF was well-tolerated by patients with neovascular age-related macular degeneration, according to results of a phase 1 clinical trial.“The phase 1 study did not reveal any treatment-emergent adverse events and no reports of inflammation,” Jeffrey S. Heier, MD, said at Angiogenesis, Exudation, and Degeneration 2015. “The treatments were well-tolerated.”